4
Changes in Ownership
MADRIGAL PHARMACEUTICALS, INC. Filed Acc 0001628280-26-015775
EVP and CFO sold 1,982 shares at an average $430.87 ($853,993)
- EVP and CFO acquired 5,215 shares (grant or award)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Dier Mardi EVP and CFO | 2026-03-04 | Grant or award 10b5-1 | +5,215 | 14,472 | D | ||
| Dier Mardi EVP and CFO | 2026-03-06 | Sale 10b5-1 | −646 | $431.94 | $279,033 | 13,826 | D |
| Dier Mardi EVP and CFO | 2026-03-06 | Sale 10b5-1 | −40 | $425.08 | $17,003 | 13,786 | D |
| Dier Mardi EVP and CFO | 2026-03-06 | Sale 10b5-1 | −420 | $426.86 | $179,283 | 13,366 | D |
| Dier Mardi EVP and CFO | 2026-03-06 | Sale 10b5-1 | −80 | $427.85 | $34,228 | 13,286 | D |
| Dier Mardi EVP and CFO | 2026-03-06 | Sale 10b5-1 | −160 | $429.00 | $68,639 | 13,126 | D |
| Dier Mardi EVP and CFO | 2026-03-06 | Sale 10b5-1 | −40 | $429.58 | $17,183 | 13,086 | D |
| Dier Mardi EVP and CFO | 2026-03-06 | Sale 10b5-1 | −120 | $430.90 | $51,708 | 12,966 | D |
| Dier Mardi EVP and CFO | 2026-03-06 | Sale 10b5-1 | −116 | $432.56 | $50,176 | 12,850 | D |
| Dier Mardi EVP and CFO | 2026-03-06 | Sale 10b5-1 | −160 | $434.20 | $69,472 | 12,690 | D |
| Dier Mardi EVP and CFO | 2026-03-06 | Sale 10b5-1 | −80 | $435.32 | $34,825 | 12,610 | D |
| Dier Mardi EVP and CFO | 2026-03-06 | Sale 10b5-1 | −80 | $436.69 | $34,935 | 12,530 | D |
| Dier Mardi EVP and CFO | 2026-03-06 | Sale 10b5-1 | −40 | $437.65 | $17,506 | 12,490 | D |
| Derivatives | |||||||
| Dier Mardi EVP and CFO | 2026-03-04 | Grant or award · Stock Option (Right to Buy) 10b5-1 | +6,519 | 6,519 | D | ||
| Open-market sales · 1,982 sh · avg $430.87 · $853,993 | |||||||
Loading xslF345X05/wk-form4_1772842708.xml…